Boundless Bio Advances Kinesin Degrader Program and Extends Cash Runway
On January 20, 2026, Boundless Bio, Inc. (Nasdaq: BOLD), a leading clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, announced significant advancements in its drug development pipeline. The U.S. Food and Drug Administration (FDA) has accepted Boundless Bio's Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. This acceptance paves the way for the company to commence its first-in-human clinical trial, KOMODO-1, intended for patients with metastatic breast cancer, set to initiate in the first half of 2026.
Details About the BBI-940 Kinesin Degrader Program
The acceptance of the BBI-940 IND represents a crucial milestone for Boundless Bio as it moves forward with its innovative approach to treating oncogene-amplified cancers. BBI-940 targets a unique kinesin involved in DNA segregation, specifically in relation to ecDNA during mitosis. In preclinical studies, BBI-940 has displayed potent anti-tumor activity in various cancer cell lines and mouse xenograft models, achieving single-agent tumor regressions.
“The acceptance of the BBI-940 IND marks an important milestone for our first-in-class Kinesin oral degrader program,” stated Zachary Hornby, President and CEO of Boundless Bio. “Our strategic portfolio prioritization ensures we remain focused on BBI-940, maximizing our potential to offer high-impact therapies where there is an unmet need.”
Changes to the Clinical Portfolio
In a strategic move, Boundless Bio has decided to discontinue enrollment in the Phase 1/2 POTENTIATE trial, which evaluated the combination of BBI-355, an oral selective CHK1 inhibitor, and BBI-825, an oral selective RNR inhibitor, for oncogene-amplified cancers. This decision stems from comprehensive market evaluations and a focus on high-potential programs that could yield significant long-term value for patients and investors alike.
Financial Position and Future Outlook
Boundless Bio's revised operational strategy is projected to extend its cash runway into the second half of 2028, aligning with the anticipated initial proof-of-concept data release for BBI-940. This optimization reflects a commitment to disciplined capital allocation and strategic project prioritization, enabling Boundless Bio to remain at the forefront of cancer therapeutic innovation.
About Boundless Bio
Boundless Bio is dedicated to advancing cancer therapeutics targeting the significant unmet needs associated with oncogene-amplified tumors. The company's research focuses on ecDNA, a common factor in oncogene amplification found in approximately 14% to 17% of cancer patients. The development of BBI-940, a potential first-in-class selective Kinesin degrader, illustrates Boundless Bio's commitment to pioneering ecDNA-directed therapeutic candidates (ecDTx).
Headquartered in San Diego, California, Boundless Bio aims to transform therapeutic landscapes for cancer patients. For further information, visit www.boundlessbio.com and follow the company on LinkedIn and X.
Forward-Looking Statements
Boundless Bio cautions that the statements in this article, which are not historical facts, constitute forward-looking statements. Potential risks and uncertainties could cause actual results to differ materially, affecting the company’s future operations and development timelines for programs like BBI-940. Investors should refer to the company’s SEC filings for more detailed risk factors.